This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Dongguk University Industry-Academic Cooperation Foundation, Korea Research Institute of Bioscience and Biotechnology, Song Ho Biomed Co., Ltd.. Active years: 2015-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 102 
2 out of 334 
1 out of 1 Years Active: 2015-2017
Title: Chang-Woo Lee: Pioneer in HIF-1α Inhibitor Innovations
Introduction
Chang-Woo Lee, based in Chungcheongbuk-do, South Korea, is a notable inventor with a focus on innovative compounds utilized in the medical field. With a total of 3 patents to his name, his contributions particularly address critical health challenges associated with various solid cancers and other diseases.
Latest Patents
One of Chang-Woo Lee's most significant patents is centered on novel compounds as HIF-1α inhibitors, alongside the manufacturing processes related to these innovations. This groundbreaking invention pertains to pharmaceutical compositions that exhibit inhibition activity against HIF-1α. These compounds have promising applications for therapeutic prevention and treatment of several solid cancers, including colon cancer, liver cancer, stomach cancer, and breast cancer. Furthermore, their utility extends to the treatment of diabetic retinopathy and rheumatoid arthritis, conditions that are exacerbated by HIF-1α-mediated VEGFA expression.
Career Highlights
Chang-Woo Lee has had an impressive career, contributing his expertise to institutions such as the Dongguk University Industry-Academic Cooperation Foundation and the Korea Research Institute of Bioscience and Biotechnology. His research endeavors have significantly influenced advancements in biochemical treatments, particularly in oncology and related fields.
Collaborations
Throughout his career, Chang-Woo Lee has collaborated with esteemed colleagues, including Hwan-Mook Kim and Song-Kyu Park. Their collective efforts further foster innovation and development within the realm of biopharmaceuticals.
Conclusion
In conclusion, Chang-Woo Lee stands out as a pioneering inventor whose work on HIF-1α inhibitors marks significant progress in medical research. His innovative compounds not only aim to combat notorious diseases but also enhance the therapeutic landscape for patients suffering from various health issues. With a commitment to research and development, Chang-Woo Lee continues to be a formidable presence in the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile